Peregrine Pharmaceuticals (NASDAQ:PPHM)

CAPS Rating: 1 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

Recs

1
Player Avatar TMFBlacknGold (98.92) Submitted: 8/13/2012 1:43:35 PM : Underperform Start Price: $0.54 PPHM Score: -131.61

This is probably the last time I red thumb a company anywhere near $0.50. Although my pick is quickly approaching -400 points - by far my worst pick active or ever - I am sure the company will fall pretty far soon enough. If only I had followed zz's green thumb at the same entry point I could have enjoyed a swing of over 500 pts. $@!%! me

Report this Post 4 Replies
Member Avatar TMFBlacknGold (98.92) Submitted: 9/7/2012 3:26:49 PM
Recs: 0

-650....crap.

Member Avatar TMFBlacknGold (98.92) Submitted: 9/24/2012 8:56:04 AM
Recs: 3

Vindication! (Although it's really just luck since I red-thumbed without looking into the company's trials in the first place)

Member Avatar TMFBlacknGold (98.92) Submitted: 12/12/2012 1:22:43 PM
Recs: 0

Can this company go away already? The leading drug candidate will likely never be successful. Add on the dilutive financing and you get the picture.

Member Avatar TMFBlacknGold (98.92) Submitted: 1/7/2013 10:47:30 AM
Recs: 0

Not again! At -250 and holding steady for the next time someone calls out this company for data dredging. Combining the placebo and 1 mg groups and then comparing it to the 3 mg groups...really? Is patient data divided by days of the week and alphabetical mother's maiden name sub groups too?

Featured Broker Partners


Advertisement